A federal judge has certified a class action antitrust suit against pharmaceuticals giant GlaxoSmithKline that accuses the company of using a series of illegal tactics to delay the approval of generic versions of Flonase, a popular allergy drug.

According to the suit, sales of Flonase peaked at $1.3 billion in 2005 — the last year of GSK’s market exclusivity.